Nektar Therapeutics (NASDAQ: NKTR) reported fourth‑quarter and full‑year 2025 financial results, showing a fourth‑quarter revenue of $21.8 million and a net loss of $36.1 million. For the full year, revenue totaled $55.2 million, a 44% decline from $98.4 million in 2024, while the company posted a net loss of $164.1 million. Cash and investments stood at $245.8 million as of December 31, 2025, giving the company a runway into the second quarter of 2027.
The sharp revenue drop reflects the company’s strategic shift away from product sales after selling its Huntsville manufacturing facility. The sale eliminated the manufacturing‑related revenue stream and cost of goods sold, leaving only non‑cash royalty revenue, which fell as the company’s licensing portfolio contracted. The remaining revenue is largely driven by royalty income from its pipeline assets, with no significant product sales in the quarter.
Nektar’s earnings per share of –$1.78 beat the consensus estimate of –$2.76 by $0.98, a substantial improvement. The beat is largely attributable to disciplined cost management and the elimination of manufacturing costs, which reduced operating expenses and improved margin on the remaining revenue. The company’s net loss narrowed from the prior year’s $119.0 million loss, reflecting lower operating costs and a one‑time impairment related to the facility sale.
Management reiterated its cash‑runway guidance, projecting sufficient liquidity to fund operations through Q2 2027. The company also provided preliminary 2026 guidance, forecasting non‑cash royalty revenue of $40–$45 million and research and development expenses of $200–$250 million, indicating continued investment in its lead candidate rezpegaldesleukin and other pipeline assets.
The market reacted positively to the results, with investors citing the strong EPS and revenue beats, the robust cash position, and the promising Phase 2 data for rezpegaldesleukin as key drivers of optimism.
CEO Howard W. Robin highlighted the significance of the Phase 2 data, noting that the results “highlight the promise and differentiation of our novel Treg mechanism in two inflammatory dermatological disease settings.” He added that the company plans to initiate a Phase 3 program for rezpegaldesleukin in atopic dermatitis in June 2026, underscoring its commitment to advancing the pipeline.
The earnings release underscores Nektar’s transition from a manufacturing‑focused business to a purely drug‑development company. While the revenue decline signals the end of legacy product sales, the company’s strong cash position and continued investment in clinical development position it for potential future growth if rezpegaldesleukin and other candidates achieve regulatory approval. Headwinds include ongoing net losses and the need for sustained R&D spending, but tailwinds such as positive clinical data and a solid financial base provide a foundation for future progress.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.